Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial of Cationic Peptide-IL22BP mRNA for Safety, Tolerability, and Preliminary Antitumor Activity in Patients With Advanced Malignant Solid Tumors

NCT07583654 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07583654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07583654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial of Cationic Peptide-IL22BP mRNA for Safety, Tolerability, and Preliminary Antitumor Activity in Patients With Advanced Malignant Solid Tumors
Lead sponsor
West China Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
July 13, 2026
Completion date
December 30, 2027
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer metastatic, mrna vaccine, peptides, solid tumor cancer